Category - Developments

Developments

Galectin completes patient recruitment in NASH trial

Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX trial. The company...

August 3, 2016

Developments

Cellect completes NASDAQ IPO

Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs. Each ADS, representing 20 ordinary...

August 3, 2016

Developments

Oramed gets additional milestone from HTIT

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a milestone payment of $4-million from Hefei Tianhui Incubator of Technologies (HTIT) of China. The milestone is part of a license and investment agreement between...

August 2, 2016

Developments

Titan’s Probuphine gains media attention in NYC

New York’s WPIX-TV has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction. The FDA...

August 1, 2016

Developments

Spartan announces first applications for Cube

Closely-held Spartan Bioscience has launched the world’s smallest commercial molecular diagnostic device, the Spartan Cube, and announced its first assay applications. They are Strep A, Apolipoprotein E, a genetic...

August 1, 2016

Developments

ProMIS releases clinical results at Alzheimer’s conference

ProMIS Neurosciences (TSX:PMN) released results in two presentations of its recent therapeutic developments at the Alzheimer’s Association International Conference in Toronto. “Our results presented at the AAIC meeting...

July 28, 2016

Developments

Oramed posts positive oral insulin data

Oramed Pharmaceuticals (NASDAQ:ORMP) reported additional data from the recently concluded Phase 2b trial of its oral insulin capsule ORMD-0801 in adults with Type 2 diabetes. The data indicate a statistically...

July 28, 2016

Developments

Anavex reports Phase 2a efficacy data in AD

Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in...

July 27, 2016

Developments

Avivagen, UNAHCO register OxC-beta in Philippines

Avivagen (TSX-V:VIV) and UNAHCO have registered OxC-beta Livestock as an imported livestock feed additive, authorizing its use in all species in the Philippines. UNAHCO is a feed and veterinary unit of Unilab, the...

July 27, 2016

Developments

Tandem expands pediatric indication of insulin pump

Tandem Diabetes Care (NASDAQ:TNDM) received FDA clearance of an expanded pediatric indication for the t:slim Insulin Pump, lowering its use to children age 6 and older from children age 12 and older. The t:slim Pump is...

July 26, 2016

Category - Developments

Galectin completes patient recruitment in NASH trial

Cellect completes NASDAQ IPO

Oramed gets additional milestone from HTIT

Titan’s Probuphine gains media attention in NYC

Spartan announces first applications for Cube

ProMIS releases clinical results at Alzheimer’s conference

Oramed posts positive oral insulin data

Anavex reports Phase 2a efficacy data in AD

Avivagen, UNAHCO register OxC-beta in Philippines

Tandem expands pediatric indication of insulin pump

General

More